These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 33756019)

  • 61. Extended-spectrum β-lactamase-producing Enterobacteriaceae, national study of antimicrobial treatment for pediatric urinary tract infection.
    Lagree M; Bontemps S; Dessein R; Angoulvant F; Madhi F; Martinot A; Cohen R; Dubos F;
    Med Mal Infect; 2018 May; 48(3):193-201. PubMed ID: 29449049
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Febrile urinary tract infection in children: ampicillin and trimethoprim insufficient as empirical mono-therapy.
    Prelog M; Schiefecker D; Fille M; Wurzner R; Brunner A; Zimmerhackl LB
    Pediatr Nephrol; 2008 Apr; 23(4):597-602. PubMed ID: 18193296
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Molecular characterization of extended spectrum β -lactamases enterobacteriaceae causing lower urinary tract infection among pediatric population.
    Eltai NO; Al Thani AA; Al-Ansari K; Deshmukh AS; Wehedy E; Al-Hadidi SH; Yassine HM
    Antimicrob Resist Infect Control; 2018; 7():90. PubMed ID: 30069306
    [TBL] [Abstract][Full Text] [Related]  

  • 64. [Clinical efficacy of T-1982 (cefbuperazone) for infections of children].
    Kurashige T; Kitamura I; Ogura H; Wakiguchi H; Morita H; Kuramitsu M; Kuroiwa Y; Tone Y; Mino M
    Jpn J Antibiot; 1983 Apr; 36(4):877-80. PubMed ID: 6876377
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Antibiotic resistance patterns of community-acquired urinary tract infections in children with vesicoureteral reflux receiving prophylactic antibiotic therapy.
    Cheng CH; Tsai MH; Huang YC; Su LH; Tsau YK; Lin CJ; Chiu CH; Lin TY
    Pediatrics; 2008 Dec; 122(6):1212-7. PubMed ID: 19047236
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing urinary tract and intraabdominal infections in Europe: report from an antimicrobial surveillance programme (2012-15).
    Pfaller MA; Bassetti M; Duncan LR; Castanheira M
    J Antimicrob Chemother; 2017 May; 72(5):1386-1395. PubMed ID: 28165526
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Diversity and trends in population structure of ESBL-producing Enterobacteriaceae in febrile urinary tract infections in children in France from 2014 to 2017.
    Birgy A; Madhi F; Jung C; Levy C; Cointe A; Bidet P; Hobson CA; Bechet S; Sobral E; Vuthien H; Ferroni A; Aberrane S; Cuzon G; Beraud L; Gajdos V; Launay E; Pinquier D; Haas H; Desmarest M; Dommergues MA; Cohen R; Bonacorsi S;
    J Antimicrob Chemother; 2020 Jan; 75(1):96-105. PubMed ID: 31617912
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Local audit: How tightly should we police antibiotic prescribing for urinary tract infection and how should we modify national policy?
    Brair A; Toozs-Hobson P; Gray J
    Post Reprod Health; 2015 Dec; 21(4):151-7. PubMed ID: 26545976
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Antibiotic treatment and antimicrobial resistance in children with urinary tract infections.
    Vazouras K; Velali K; Tassiou I; Anastasiou-Katsiardani A; Athanasopoulou K; Barbouni A; Jackson C; Folgori L; Zaoutis T; Basmaci R; Hsia Y
    J Glob Antimicrob Resist; 2020 Mar; 20():4-10. PubMed ID: 31252156
    [TBL] [Abstract][Full Text] [Related]  

  • 70. [Fundamental and clinical studies of T-1982 (cefbuperazone) in the pediatric field].
    Motohiro T; Koga T; Tomita N; Fujimoto T; Nishiyama T; Ishimoto K; Tominaga K; Yamashita F; Koga Y; Takajo N; Araki H; Tanaka K; Imai S; Yuasa T; Nagayama K; Tsugawa S; Tanaka Y; Shimada Y; Aramaki S; Iriki T; Cho H; Yamamoto M; Komatsu Y; Tanaka C; Yuge K; Toyoda A; Matsunaga S; Yukizane S; Takechi T; Matsuo H; Eto Y; Matsuyuki M
    Jpn J Antibiot; 1983 Apr; 36(4):888-909. PubMed ID: 6348343
    [No Abstract]   [Full Text] [Related]  

  • 71. Changing trend in antimicrobial resistance of pediatric uropathogens in Taiwan.
    Tseng MH; Lo WT; Lin WJ; Teng CS; Chu ML; Wang CC
    Pediatr Int; 2008 Dec; 50(6):797-800. PubMed ID: 19067894
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Oral cephalosporin and β-lactamase inhibitor combinations for ESBL-producing Enterobacteriaceae urinary tract infections.
    Stewart AG; Harris PNA; Henderson A; Schembri MA; Paterson DL
    J Antimicrob Chemother; 2020 Sep; 75(9):2384-2393. PubMed ID: 32443141
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Drug-resistant Enterobacteriaceae colonization is associated with healthcare utilization and antimicrobial use among inpatients in Pune, India.
    Bharadwaj R; Robinson ML; Balasubramanian U; Kulkarni V; Kagal A; Raichur P; Khadse S; Kadam D; Valvi C; Kinikar A; Kanade S; Suryavanshi N; Marbaniang I; Nelson G; Johnson J; Zenilman J; Sachs J; Gupta A; Mave V
    BMC Infect Dis; 2018 Oct; 18(1):504. PubMed ID: 30286741
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Noncarbapenems for the Treatment of Urinary Tract Infections Caused by Extended-Spectrum β-Lactamase-Producing Bacteria.
    White CW; Kyle JA; Deas CM; Campbell J
    South Med J; 2019 Aug; 112(8):438-443. PubMed ID: 31375841
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Antimicrobial therapy of urinary tract infections in children.
    Beetz R; Westenfelder M
    Int J Antimicrob Agents; 2011 Dec; 38 Suppl():42-50. PubMed ID: 22036250
    [TBL] [Abstract][Full Text] [Related]  

  • 76. [Clinical evaluation of cephalexin and cephaloglycin for lower urinary tract infection].
    Akasaka H; Imamura K; Kai Y; Yoshida H; Nakano H
    Hinyokika Kiyo; 1969 Sep; 15(9):677-88. PubMed ID: 5390332
    [No Abstract]   [Full Text] [Related]  

  • 77. Antimicrobial Resistance and Diagnostic Imaging in Infants Younger Than 2 Months Old Hospitalized With a First Febrile Urinary Tract Infection: A Population-based Comparative Study.
    Hsu CC; Tsai JD; Ku MS; Chen SM; Liao PF; Hung TW; Tsai ML; Sheu JN
    Pediatr Infect Dis J; 2016 Aug; 35(8):840-5. PubMed ID: 27100129
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Increased community-acquired upper urinary tract infections caused by extended-spectrum beta-lactamase-producing Escherichia coli in children and the efficacy of flomoxef and cefmetazole.
    Horie A; Nariai A; Katou F; Abe Y; Saito Y; Koike D; Hirade T; Ito T; Wakuri M; Fukuma A
    Clin Exp Nephrol; 2019 Nov; 23(11):1306-1314. PubMed ID: 31428892
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Etiology and antimicrobial resistance patterns in pediatric urinary tract infection.
    Wang J; He L; Sha J; Zhu H; Huang L; Zhu X; Dong J; Li G; Ge Z; Lu R; Ma G; Shi Y; Guo Y
    Pediatr Int; 2018 May; 60(5):418-422. PubMed ID: 29394522
    [TBL] [Abstract][Full Text] [Related]  

  • 80. [Clinical experience with T-1982 (cefbuperazone) in the pediatric field].
    Miyauchi Y; Nishimori M; Asano E; Sakaguchi Z; Ohara K; Okamoto T
    Jpn J Antibiot; 1983 Apr; 36(4):855-61. PubMed ID: 6348340
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.